Dendritic cells as therapeutic vaccines against cancer

By Jacques Banchereau, A. Palucka. Nature reviews. Immunology, 2005

1,257 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy (2008, positive): “, 2008); dendritic cells can present tumor antigens to activate an anti-tumor immune response (Banchereau and Palucka, 2005); and T-regulatory lymphocytes (Tregs) can downregulate the activity of cytotoxic T-lymphocytes against cancer cells (Colombo and Piconese, 2007).”
Inhibitory B7-family molecules in the tumour microenvironment (2008, background): “Three important mediators of this evasion of tumour immunity that have been identified in the tumour microenvironment are: dysfunctional antigen-presenting cells (APCs), including dendritic cells (DCs), macrophage”
The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. (2013, background): “Csf-2 is a cytokine that is critical for promoting the differentiation of mouse and human hematopoietic progenitors and monocytes into cells that resemble mouse splenic cDCs (83, 108, 109) and remains to date a key cytokine for generating DC-based vaccines for clinical use (110).”
VEGF-targeted therapy: mechanisms of anti-tumour activity (2008, background): “DCs are bone marrow-derived antigen-presenting cells that have a crucial role in initiating immune responses against foreign pathogen”